Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer
- Sponsor
- Henan Cancer Hospital
- Study ID
- NCT03389087
- Phase
- PHASE2
- Status
- Unknown
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Apatinib and Etoposide Capsule — DRUGApatinib 250mg/qd，po, A course of treatment need 28 days. Etoposide Capsule 25mg/d，po, from day 1-day 21.
Study Details
The purpose of this study is to confirm the safety and efficacy of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer.
Key Dates
- Start date
- Nov 29, 2017
- Status verified
- Jun 2020
- Primary completion
- Nov 1, 2019
- Completion
- Nov 1, 2021
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Apatinib and Etoposide CapsuleApatinib and Etoposide Capsule
Primary Outcome Measure
Progression-free Survival (PFS) [ Time Frame: up to 2 year ]
Related Studies
- Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial TumorsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56PHASE1/PHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · New York, New York
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- Tempus Small Cell Lung Cancer Observational Study (Sculptor)Recruiting · Tempus AI · Los Alamitos, California